Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.

Abstract

BACKGROUND AND OBJECTIVES:

Autologous stem cell transplantation is a therapeutic option for chronic myeloid leukemia (CML) patients who are not candidates for allogeneic transplant. To reduce the risk of post-autografting disease recurrence, different strategies of stem cell selection have been attempted. The results of using recombinant human granulocyte colony-stimulating factor (rHuG-CSF) for harvesting hematopoietic progenitors in CML patients treated with interferon-a (IFN) are reported.

DESIGN AND METHODS:

Twenty-one CML patients who received IFN for a median of 21 (8-68) months were mobilized with rHuG-CSF (10 mg/kg/day). Twelve were in complete (CCR) or major (MCR) cytogenetic response. Complete success was considered a sufficient harvest (> 1 x 10(6)/kg CD34(+) cells/kg) without Philadelphia (Ph)+ metaphases in at least one apheresis; a partial success was a sufficient harvest with 1-35% Ph(+) cells.

RESULTS:

A total of 78 aphereses were performed. No patient had major side-effects. The median number (range) of mononuclear and CD34(+) cells obtained was, respectively, 8.6 x 10(8)/kg (0.9-22.6) and 3.3 x 10(6)/kg (0.4-26.3) per patient. A sufficient cell yield was collected in all but three patients. A complete/partial success was achieved in seven CCR/MCR patients (63%) and in three (33%) with other responses. Four patients underwent successful autografting using the stem cells obtained after rHuG-CSF mobilization.

INTERPRETATION AND CONCLUSIONS:

Mobilization of IFN-treated patients using rHuG-CSF is safe and provides a significant proportion of Ph-negative progenitors in CML patients in complete or major cytogenetic response.

• Authors: Juan-Carlos Hernández-Boluda, Enric Carreras, Francisco Cervantes, Pedro Marín, Eduardo Arellano-Rodrigo, Montserrat Rovira, Francesc Solé, Elisabet Lloveras, Blanca Espinet, Agustín Ocejo, Emili Montserrat
• Journal: Haematologica (Haematologica) Vol. 87 Issue 1 Pg. 17-22 (Jan 2002) ISSN: 0390-6078 [Print] Italy
• PMID: 11801461 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunologic Factors
• Recombinant Proteins
• Cytarabine
• Granulocyte Colony-Stimulating Factor
• Interferons
• Busulfan
• Filgrastim
• Hydroxyurea

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Blood Cell Count
• Blood Component Removal
• Bone Marrow Purging (methods, statistics & numerical data)
• Busulfan (administration & dosage, therapeutic use)
• Cytarabine (therapeutic use)
• Feasibility Studies
• Female
• Filgrastim
• Granulocyte Colony-Stimulating Factor (adverse effects, pharmacology)
• Hematopoietic Stem Cell Mobilization (methods)
• Hematopoietic Stem Cell Transplantation (statistics & numerical data)
• Hematopoietic Stem Cells (cytology)
• Humans
• Hydroxyurea (administration & dosage, therapeutic use)
• Immunologic Factors (therapeutic use)
• Interferons (therapeutic use)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood, drug therapy, therapy)
• Leukocytosis (chemically induced)
• Male
• Middle Aged
• Neoplastic Cells, Circulating
• Pain (chemically induced)
• Philadelphia Chromosome
• Recombinant Proteins
• Remission Induction
• Safety
• Transplantation, Autologous
• Treatment Outcome